Aegerion (AEGR) Trading Halted Ahead of Lomitapide FDA Committee Meeting
Tweet
Share
E-mailGet Alerts AEGR Hot Sheet
Join SI Premium – FREE
Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced that NASDAQ has halted trading of the company's common stock today. The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) is meeting today to discuss the company's New Drug Application (NDA) for lomitapide.
Aegerion is seeking FDA marketing approval of lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in adult patients with Homozygous Familial Hypercholesterolemia (HoFH). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of December 29, 2012 for completion of its review of the NDA for lomitapide.
Aegerion is seeking FDA marketing approval of lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in adult patients with Homozygous Familial Hypercholesterolemia (HoFH). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of December 29, 2012 for completion of its review of the NDA for lomitapide.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Amplitude Therapeutics signs taRNA vaccine deal with Eli Lilly
- Propanc Biopharma begins prep for Phase 1b cancer therapy trial in Australia
Create E-mail Alert Related Categories
FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
